Secretome Therapeutics Secures $30 Million Series A to Advance Cardiac Cell Therapy for Duchenne Muscular Dystrophy
Key Insights
Secretome Therapeutics (search) closed a $30 million Series A financing led exclusively by RA Capital Management (search) to advance its neonatal cardiac progenitor cell therapy platform.
The funding will support late-stage clinical trials of STM-01, a cellular therapy targeting Duchenne muscular dystrophy (search)-associated cardiomyopathy (search), moving toward pivotal Phase 2 and Phase 3 development.
STM-01 represents an innovative approach to cardiac regeneration by addressing inflammation and fibrosis pathways in heart disease, with potential applications for other rare cardiomyopathies.
Secretome Therapeutics (search), a clinical-stage biotechnology company developing regenerative cardiac therapies, announced the closing of a $30 million Series A financing from RA Capital Management (search). The investment will support the advancement of STM-01, an innovative neonatal cardiac progenitor cell (nCPC)-derived therapy targeting Duchenne muscular dystrophy (search)-associated cardiomyopathy (search) and other rare forms of cardiomyopathy secondary to neuromuscular disease.
The Series A round was led exclusively by RA Capital Management (search), a multi-stage investment manager dedicated to evidence-based investing in healthcare and life sciences companies. The funding will enable Secretome to advance STM-01 toward pivotal Phase 2 and Phase 3 development in Duchenne muscular dystrophy (search), an indication with few disease-modifying therapeutic options.
STM-01: Targeting Cardiac Regeneration in Duchenne Muscular Dystrophy
STM-01 represents Secretome's most advanced program, designed as a cellular therapy for the restoration and regeneration of cardiac function. The therapy specifically targets Duchenne muscular dystrophy (search)-associated cardiomyopathy (search), a progressive and severe manifestation of the disease process involving the heart.
The therapeutic approach focuses on addressing both inflammatory response and fibroblastic remodeling of heart muscle. STM-01 is engineered to promote damaged heart tissue regeneration through therapies derived from neonatal cardiac progenitor cells (search) that target inflammation and fibrosis pathways central to cardiac disease progression.
Beyond Duchenne muscular dystrophy (search), Secretome is investigating the platform technology's application to other forms of cardiac dysfunction, including dilated cardiomyopathy (search) and heart failure (search) with preserved ejection fraction, conditions that currently lack effective treatments for affected patient populations globally.
Strategic Investment and Leadership Changes
The exclusive investment from RA Capital signals strong confidence in Secretome's scientific platform and STM-01's potential as a best-in-class therapy. Matthew Hammond, Ph.D., MBA, a Partner at RA Capital Management (search), will serve as Board Observer, providing governance support and strategic oversight.
In connection with the financing, David Lubner joined Secretome's Board of Directors, while Dr. Charles Edwards resigned from the Board. Lubner brings over 25 years of experience as a senior executive and Board member in the life sciences industry. He previously served as Executive Vice President and Chief Financial Officer of Ra Pharmaceuticals until its acquisition by UCB (search) in 2020, and held CFO positions at Tetraphase Pharmaceuticals, PharMetrics, and ProScript.
Lubner currently serves on the boards of Crescent Bio and Dyne Therapeutics, and previously served on boards of companies including Arcellx (acquired by Gilead in April 2026), Nightstar Therapeutics (acquired by Biogen), and POINT Biopharma (acquired by Eli Lilly).
Platform Development and Manufacturing Expansion
The Series A funding will support multiple aspects of Secretome's development strategy, including company operations, manufacturing capacity expansion for upcoming clinical trials, and regulatory preparation. The capital will be allocated toward study site identification, patient selection, recruitment, and logistical planning for late-stage studies.
Secretome's pipeline includes STM-01 as the lead clinical candidate and STM-21 in preclinical development stages. The platform is designed to restore heart function through biological regeneration, targeting inflammation and fibrosis pathways in cardiac disease.
The Texas-based company aims to deliver disease-modifying therapies for cardiac patients through an approach focused on repairing underlying biological damage. The next phase will concentrate on clinical validation and therapeutic scaling, with successful outcomes potentially positioning STM-01 as a breakthrough therapy in the high-need therapeutic category of cardiac regenerative medicine.